Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-12-3544-3939
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$56.50 million
Profitability
Miscellaneous
Employees61
Next Earnings Date9/19/2019 (Estimated)
OptionableOptionable
SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions
What is SUMMIT THERAPEU/S's stock symbol?
SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."
How were SUMMIT THERAPEU/S's earnings last quarter?
SUMMIT THERAPEU/S (NASDAQ:SMMT) announced its earnings results on Wednesday, March, 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.13. The business had revenue of $0.66 million for the quarter, compared to analysts' expectations of $4.44 million. SUMMIT THERAPEU/S had a net margin of 24.32% and a return on equity of 26.31%. View SUMMIT THERAPEU/S's Earnings History.
When is SUMMIT THERAPEU/S's next earnings date?
What price target have analysts set for SMMT?
2 Wall Street analysts have issued 1 year price objectives for SUMMIT THERAPEU/S's shares. Their forecasts range from $2.00 to $2.00. On average, they expect SUMMIT THERAPEU/S's stock price to reach $2.00 in the next year. This suggests a possible upside of 42.3% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S.
What is the consensus analysts' recommendation for SUMMIT THERAPEU/S?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SUMMIT THERAPEU/S.
Has SUMMIT THERAPEU/S been receiving favorable news coverage?
Media coverage about SMMT stock has trended somewhat positive on Monday, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. SUMMIT THERAPEU/S earned a news impact score of 0.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for SUMMIT THERAPEU/S.
Who are some of SUMMIT THERAPEU/S's key competitors?
Some companies that are related to SUMMIT THERAPEU/S include Acasti Pharma (ACST), Paratek Pharmaceuticals (PRTK), Imprimis Pharmaceuticals (IMMY), Mustang Bio (MBIO), Tyme Technologies (TYME), American Brivision (Holding) (ABVC), Axovant Gene Therapies (AXGT), Adamas Pharmaceuticals (ADMS), REDHILL BIOPHAR/S (RDHL), XOMA (XOMA), Newron Pharmaceuticals (NWPHF), BioXcel Therapeutics (BTAI), Hookipa Pharma (HOOK), Generex Biotechnology (GNBT) and Northwest Biotherapeutics (NWBO).
What other stocks do shareholders of SUMMIT THERAPEU/S own?
Who are SUMMIT THERAPEU/S's key executives?
SUMMIT THERAPEU/S's management team includes the folowing people:
- Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
- Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
- Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
- Ms. Melissa Strange FCCA, VP of Fin. & Company Sec. (Age 39)
- Ms. Michelle Avery, Director of Investor Relations
When did SUMMIT THERAPEU/S IPO?
(SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.
Who are SUMMIT THERAPEU/S's major shareholders?
SUMMIT THERAPEU/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Morgan Stanley (1.76%) and Bank of New York Mellon Corp (1.57%).
Which institutional investors are buying SUMMIT THERAPEU/S stock?
SMMT stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and Morgan Stanley.
How do I buy shares of SUMMIT THERAPEU/S?
Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is SUMMIT THERAPEU/S's stock price today?
One share of SMMT stock can currently be purchased for approximately $1.4050.
How big of a company is SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S has a market capitalization of $45.10 million and generates $56.50 million in revenue each year. The company earns $9.99 million in net income (profit) each year or $0.84 on an earnings per share basis. SUMMIT THERAPEU/S employs 61 workers across the globe.View Additional Information About SUMMIT THERAPEU/S.
What is SUMMIT THERAPEU/S's official website?
How can I contact SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]ummitplc.com.
MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)
MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
